"Nous vous prenons en charge pour vos soins oncologiques. Nos professionnels disposent de matériel de haute technologie pour vos traitements de chimiothérapie et de radiothérapie. Nous vous proposons des consultations avant et après le traitement pour vous accompagner de façon personnalisée. Pour plus d'informations, consultez notre site internet."

During the past decade, Institut de cancerologie du Gard conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 3 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut de cancerologie du Gard" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "ARCAGY/ GINECO GROUP" with 3 trials sponsored, "Centre Hospitalier Universitaire de Nice" with 1 trials sponsored, "Constellation Pharmaceuticals" with 1 trials sponsored and "Institut du Cancer de Montpellier - Val d'Aurelle" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut de cancerologie du Gard" #1 collaborator was "Acute Leukemia French Association" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Chugai" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Institut de cancerologie du Gard" are "Breast Cancer" (3 trials), "Acute Myeloid Leukemia" (1 trials), "Carcinoma, Renal Cell" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Chronic Lymphoid Leukemia" (1 trials). Many other conditions were trialed in "Institut de cancerologie du Gard" in a lesser frequency.

Most popular intervention types in "Institut de cancerologie du Gard" are "Drug" (14 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (3 trials), "Placebo" (3 trials), "Trastuzumab" (3 trials), "5-Fluorouracil" (2 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institut de cancerologie du Gard" are 13 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Institut de cancerologie du Gard". 2 are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Institut de cancerologie du Gard, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut de cancerologie du Gard, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".